[go: up one dir, main page]

MX2017008072A - Formulaciones de un inhibidor de pi3k/mtor para administracion intravenosa. - Google Patents

Formulaciones de un inhibidor de pi3k/mtor para administracion intravenosa.

Info

Publication number
MX2017008072A
MX2017008072A MX2017008072A MX2017008072A MX2017008072A MX 2017008072 A MX2017008072 A MX 2017008072A MX 2017008072 A MX2017008072 A MX 2017008072A MX 2017008072 A MX2017008072 A MX 2017008072A MX 2017008072 A MX2017008072 A MX 2017008072A
Authority
MX
Mexico
Prior art keywords
pi3k
formulations
intravenous administration
mtor inhibitor
enyl
Prior art date
Application number
MX2017008072A
Other languages
English (en)
Other versions
MX380172B (es
Inventor
Richard Back Kevin
Cram Michael
James Harper Aidan
James Huang W
Richard Lillis Jonathan
Michael Lukas Timothy
Luthra Sumit
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2017008072A publication Critical patent/MX2017008072A/es
Publication of MX380172B publication Critical patent/MX380172B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con una formulación farmacéutica acuosa que comprende 1-(4-{[4-(dimetilamino)piperidin -1-il]carbonil}enil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-iI )enil]urea, o una sal farmacéuticamente aceptable de la misma, que es una solución transparente; tal formulación es particularmente adecuada para administración intravenosa o parenteral a un paciente.
MX2017008072A 2014-12-17 2015-12-10 Formulaciones de un inhibidor de pi3k/mtor para administracion intravenosa. MX380172B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462093060P 2014-12-17 2014-12-17
US201562250633P 2015-11-04 2015-11-04
PCT/IB2015/059515 WO2016097949A1 (en) 2014-12-17 2015-12-10 Formulations of a pi3k/mtor-inhibitor for intravenous administration

Publications (2)

Publication Number Publication Date
MX2017008072A true MX2017008072A (es) 2017-09-28
MX380172B MX380172B (es) 2025-03-12

Family

ID=54937330

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008072A MX380172B (es) 2014-12-17 2015-12-10 Formulaciones de un inhibidor de pi3k/mtor para administracion intravenosa.

Country Status (25)

Country Link
US (2) US10172942B2 (es)
EP (1) EP3233054B1 (es)
JP (1) JP6420753B2 (es)
KR (1) KR102016822B1 (es)
CN (1) CN107205923B (es)
AU (1) AU2015365497B2 (es)
CA (1) CA2915199C (es)
CY (1) CY1124527T1 (es)
DK (1) DK3233054T3 (es)
ES (1) ES2881214T3 (es)
HR (1) HRP20211446T1 (es)
HU (1) HUE055928T2 (es)
IL (1) IL252158B (es)
LT (1) LT3233054T (es)
MX (1) MX380172B (es)
NZ (1) NZ731518A (es)
PL (1) PL3233054T3 (es)
PT (1) PT3233054T (es)
RS (1) RS62337B1 (es)
RU (1) RU2672875C1 (es)
SG (1) SG11201703826TA (es)
SI (1) SI3233054T1 (es)
TW (1) TWI660729B (es)
WO (1) WO2016097949A1 (es)
ZA (1) ZA201703764B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3672571T (lt) 2017-08-25 2021-12-10 Pfizer Inc. Farmacinė vandeninė vaisto forma, apimanti 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]karbamidą
DK3810089T3 (en) * 2018-06-07 2023-09-25 Pfizer Vandig formulering omfattende 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
MX2024001266A (es) 2021-07-26 2024-04-16 Celcuity Inc 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-d imorfolin-4-il-1,3,5-triazin-2-il)fenil]urea (gedatolisib) y sus combinaciones para usarse en el tratamiento de cancer.
WO2025128712A1 (en) 2023-12-12 2025-06-19 Celcuity Inc. Treatment of ocular diseases using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl)phenyl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phenyl]urea

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
CN101257903A (zh) * 2005-05-27 2008-09-03 拜耳医药保健股份公司 用于癌症治疗的包括二芳基脲化合物和PI3、AKT激酶或mTOR抑制剂(雷帕霉素类)的组合治疗
US20080234262A1 (en) * 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
DE202008001253U1 (de) * 2008-01-28 2008-04-10 Mirror Image Ag Bildanzeigegerät
DK3216793T3 (da) * 2008-05-23 2019-05-06 Wyeth Llc Triazinforbindelser som p13-kinase- og mtor-inhibitorer
WO2009146406A1 (en) * 2008-05-30 2009-12-03 Genentech, Inc. Purine pi3k inhibitor compounds and methods of use
WO2010096619A1 (en) 2009-02-23 2010-08-26 Wyeth Llc Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
EP2919759A4 (en) * 2012-11-14 2016-07-20 Ohio State Innovation Foundation MATERIALS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMES
US9962373B2 (en) * 2013-03-14 2018-05-08 Abraxis Bioscience, Llc Methods of treating bladder cancer
DK3116547T3 (da) * 2014-03-14 2019-07-15 Pfizer Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf

Also Published As

Publication number Publication date
LT3233054T (lt) 2021-07-26
US20190105390A1 (en) 2019-04-11
RS62337B1 (sr) 2021-10-29
CA2915199C (en) 2018-11-06
IL252158B (en) 2021-01-31
ZA201703764B (en) 2020-11-25
ES2881214T3 (es) 2021-11-29
CA2915199A1 (en) 2016-06-17
US10172942B2 (en) 2019-01-08
BR112017010841A2 (pt) 2017-12-26
AU2015365497A1 (en) 2017-06-01
CN107205923A (zh) 2017-09-26
US10660959B2 (en) 2020-05-26
HRP20211446T1 (hr) 2021-12-24
JP6420753B2 (ja) 2018-11-07
EP3233054A1 (en) 2017-10-25
NZ731518A (en) 2019-03-29
TWI660729B (zh) 2019-06-01
AU2015365497B2 (en) 2020-07-02
DK3233054T3 (da) 2021-08-02
CY1124527T1 (el) 2022-07-22
KR20170082638A (ko) 2017-07-14
SG11201703826TA (en) 2017-07-28
WO2016097949A1 (en) 2016-06-23
EP3233054B1 (en) 2021-06-30
PT3233054T (pt) 2021-08-02
RU2672875C1 (ru) 2018-11-20
JP2016113461A (ja) 2016-06-23
MX380172B (es) 2025-03-12
HUE055928T2 (hu) 2022-01-28
KR102016822B1 (ko) 2019-08-30
US20170360935A1 (en) 2017-12-21
SI3233054T1 (sl) 2021-11-30
PL3233054T3 (pl) 2021-12-20
IL252158A0 (en) 2017-07-31
TW201632188A (zh) 2016-09-16
CN107205923B (zh) 2021-03-05

Similar Documents

Publication Publication Date Title
CO2021005532A2 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
MX2016005394A (es) Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4.
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX2018000916A (es) Derivados de benzodiazepina como inhibidores de rsv.
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
MX2015010971A (es) Derivado novedoso de pirazol.
AR096543A1 (es) INHIBIDORES DE QUINASA PI3 d Y g SELECTIVOS DUALES
MX380798B (es) Profármacos de alvocidib que tienen una biodisponibilidad aumentada.
UY35684A (es) Formulación de inhibidores de la tirosina quinasa de bazo (syk)
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
MX2016008665A (es) Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo.
AR103680A1 (es) Inhibidores selectivos de bace1
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
NZ752587A (en) Lsd1 inhibitors and medical uses thereof
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
CY1124527T1 (el) Σκευασματα αναστολεα pi3k/mtor για ενδοφλεβια χορηγηση
CO2018001383A2 (es) Derivados de n-[piridin-4-il]metil]-4-{(1r)-1-[(3s)-3-metil-2,5-dioxopirrolidin-3-il]etil}benzamida como antagonistas del receptor cgrp”
UY36123A (es) Derivados de carboxamida
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX390841B (es) Preparacion liquida parenteral que comprende compuesto de carbamato.
EA201791397A1 (ru) СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
AR134057A2 (es) Composición farmacéutica en solución acuosa
MX375934B (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.